StockData

CRISPR Therapeutics vs Metagenomi Therapeutics

CRSP and MGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRSP and MGX compare

CRISPR Therapeutics is the larger company, worth 163 times as much as Metagenomi Therapeutics ($3.9B against $23.8M).

CRISPR Therapeutics scores higher on the StockData Score (8 against 6 for Metagenomi Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRSPMGX
Size and price
Market cap$3.9B$23.8M
Share price$40.15$0.631
Change, 1 year−23.6%−63.7%
Change, 5 years−49.0%–
Beta (5Y)1.591.85
Employees393119
StockData Score
Total score8 (better)6
Valuation score01 (better)
Growth score1 (better)0
Performance score2 (better)0
Health score55
Dividend score00
Valuation
P/S290×–
P/B2.2×0.2× (better)
FCF yield−9.6% (better)−360%
Growth
Revenue growth (TTM)−64.8%–
Revenue growth, 5Y average37.3%–
Profitability
Operating margin−3990%–
Net margin−3369%–
FCF margin−2773%–
Return on equity−26.1% (better)−60.6%
Financial health
Debt / equity0.000.00
Current ratio17.85 (better)4.50
Altman Z-score1.79 (better)−3.92
Piotroski F-score22
Dividends and buybacks
Buyback yield−10.0%–
Shareholder yield−10.0%0.00% (better)
Ownership
Held by institutions78.9%16.6%
Held by insiders2.7%10.4%
Insider net buying, 12 months−$17.9M−$9.7K (better)
Short interest, % of float18.3%3.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.